Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05548621 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC)

Study acronym: SDM-RCC
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 15, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Sep 2024 to Sep 2025
    • Study completion date: Oct 2024 to Dec 2025
    v4
  2. Enrollment target: 260 to 180v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 2022 to Nov 24, 2022
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to evaluate the effect of two decision aids for renal cell carcinoma (RCC) on the decision-making process and the quality of the decision.
Trial Details
NCT Number NCT05548621
Lead Sponsor St. Antonius Hospital
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Renal Cell Carcinoma, Renal Cell Carcinoma Metastatic
Related terms Carcinoma, Renal Cell
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov